MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Assets · Q3 FY2026 · quarter ended Sep 2026
Total assets rises 25.1% from a year ago
Total assets stood at $500.62M at the end of Q3 FY2026, up 25.1% from a year earlier and up 14.8% from the prior quarter. Over 3 fiscal years it compounded at +104.4% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +25.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 385.14M USD
- Year-over-year change
- +43.4%
- 3-year CAGR
- +104.4%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 385.14M | +43.4% |
| FY2024 | 2024-12-31 | 268.54M | +219.0% |
| FY2023 | 2023-12-31 | 84.18M | +86.7% |
| FY2022 | 2022-12-31 | 45.1M | — |
Total Assets vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +25.1% is the 4th highest of 8, against a peer median of +24.3%.
- Over three fiscal years its annual growth of +104.4% compares with a peer median of +7.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | €2.43B EUR | +110.2% | +6.1% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $1.21B USD | — | — |
| Jun 2026 | $521.9M USD | -37.0% | +61.9% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $500.62M USD | +25.1% | +104.4% |
| Sep 2026 | $443.13M USD | -12.6% | +7.9% | |
| Mar 2026 | $392.01M USD | +24.3% | +3.6% | |
| Mar 2026 | $335.63M USD | +113.4% | +10.6% | |
| Mar 2026 | $268.85M USD | +82.2% | +12.6% | |
| Mar 2026 | $46.39M USD | -15.7% | -23.2% | |
| Peer median (excluding MBX) | — | +24.3% | +7.9% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.